Baseline and follow-up samples in the study population (N=4043)
| No. (%) | |||||
| Age at baseline (years) | 50–54 n=1138 | 55–59 n=1277 | 60–64 n=1218 | 65+ n=410 | Total N=4043 |
| Baseline | |||||
| Cytology alone | |||||
| ASCUS+ | 70 (6.2) | 34 (2.7) | 35 (2.9) | 15 (3.7) | 154 (3.8) |
| ASCUS | 41 (3.6) | 18 (1.4) | 21 (1.7) | 6 (1.5) | 86 (2.1) |
| LSIL | 9 (0.8) | 5 (0.4) | 6 (0.5) | 2 (0.5) | 22 (0.5) |
| HSIL+* | 20 (1.8) | 11 (0.9) | 8 (0.7) | 7 (1.7) | 46 (1.1) |
| Cytology/HPV triage | |||||
| Positive† | 36 (3.2) | 20 (1.6) | 13 (1.1) | 10 (2.4) | 79 (2.0) |
| HPV alone | |||||
| HPV 16/18‡ | 31 (2.7) | 25 (2.0) | 20 (1.6) | 8 (2.0) | 84 (2.1) |
| HrHPV other types only | 91 (8.0) | 73 (5.7) | 60 (4.9) | 16 (3.9) | 240 (5.9) |
| HPV/cytology triage | |||||
| Positive*§ | 52 (4.6) | 32 (2.5) | 23 (1.9) | 13 (3.2) | 120 (3.0) |
| Follow-up | |||||
| At least one histology | 225 (19.8) | 188 (14.7) | 148 (12.2) | 79 (19.3) | 640 (15.8) |
| At least one cytology | 977 (85.9) | 1098 (86.0) | 462 (37.9) | 279 (68.0) | 2816 (69.7) |
| Total with follow-up result | 998 (87.7) | 1124 (88.0) | 506 (41.5) | 303 (73.9) | 2931 (72.5) |
| Worst histology | n=225 | n=188 | n=148 | n=79 | n=640 |
| CIN2+¶ | 25 (11.1) | 18 (9.6) | 15 (10.1) | 6 (7.6) | 64 (10.0) |
| CIN3+** | 18 (8.0) | 9 (4.8) | 8 (5.4) | 5 (6.3) | 40 (6.3) |
Percentages are per column.
*HSIL+ included HSIL, AGC, adenoCIS, ASCH, and malignant cells from cervical cancer.
†including HSIL+ and ASCUS/LSIL with concurrent positive hrHPV test result (all hr-types).
‡19 women had both HPV 16/18 and other types.
§including all HPV 16/18 positive and hrHPV other types with concurrent ASCUS+.
¶CIN2+ includes CIN2, CIN not specified, and diagnoses included in definition of CIN3+.
**CIN3 +includes CIN3, adenoCIS, AGC, and cervical cancer.